- Around 450,000 people globally are estimated to be living with a CAH disorder yet there is no standard treatment.
- CAH is associated with over-production of male sex hormones resulting in ambiguous genitalia at birth, precocious sexual development, infertility in men and women, and increased mortality through adrenal crisis.
Diurnal Group plc (AIM: DNL), will be presenting research findings on the treatment and management of congenital adrenal hyperplasia (CAH) at this year’s American Endocrine Society meeting, ENDO 2022, which will be taking place between 11-14 June 2022 in Atlanta, USA.
Over the four-day meeting, the following topics will be presented:
- Comparison of prednisolone versus hydrocortisone modified-release hard capsules (Efmody®) in the treatment of CAH.
- A de novo model for measuring long-term health effects of hydrocortisone modified-release hard capsules in adult and adolescent patients with classic CAH.
CAH occurs when the production of cortisol from the adrenal gland is limited due to a genetic deficiency. CAH is associated with over-production of male sex hormones resulting in ambiguous genitalia at birth, precocious sexual development, infertility in men and women, and increased mortality through adrenal crisis.
Around 450,000 people globally are estimated to be living with a CAH disorder yet there is no standard treatment. Instead, a variety of steroids are used but data shows around two thirds of people living with CAH still have problems with disease control[i].
Richard Bungay, Interim Chief Executive Officer of Diurnal commented:
"These presentations at ENDO follow our very well attended presentations at the European Congress of Endocrinology meeting in Europe last month. Diurnal is committed to supporting research into diseases of cortisol deficiency and developing solutions to support patients with these life-long disorders. The interest we have received from the world’s leading endocrinologists demonstrates the progress we are making in the treatment and management of diseases of cortisol deficiency.”
 Mallappa, A., Merke, D.P. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol 18, 337–352 (2022). https://doi.org/10.1038/s41574-022-00655-w
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information, please contact:
Diurnal Group plc
Richard Bungay, Interim Chief Executive Officer: +44 (0)20 3727 1000
Vane Percy & Roberts
Simon Vane Percy: +44 (0) 7710 005 910